Antitumor Activity of Imidazothioxanthones in Murine and Human Tumor Models In Vitro and In Vivo

Anticancer Research

Volumn 24, Issue 2 B, 2004, Pages 907-919

  Varvaresou, A ^b,g   Iakovou, K ^b   Gikas, E ^b   Fichtner, I ^c   Fiebig, H H ^d   Kelland, L R ^e   Double, J A ^f   Bibby, M C ^f   Hendriks, H R ^a,h  

^a EORTC New Drug Development Office   (Netherlands)

^b UNIVERSITY OF ATHENS   (Greece)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d CHARLES RIVER LABORATORIES   (United States)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f UNIVERSITY OF BRADFORD   (United Kingdom)

^g UNIVERSITY OF WEST ATTICA   (Greece)

^h Hendriks Pharmaceutical Consulting   (Netherlands)

Author keywords

Antitumor activity; Cytotoxicity; Human tumor xenografts; Imidazothioxanthones; Molecular modeling docking; Murine tumors

Indexed keywords

11 OXO N [2 (PIPERIDINO)ETHYLO] 11H BENZOTHIOPYRANO[3',2':2,3]PYRIDO[1,2 A]IMIDAZO 2 CARBOXAMIDE; 11 OXO N [2 (PYRROLIDINO)ETHYLO] 11H BENZOTHIOPYRANO[3',2':2,3]PYRIDO[1,2 A]IMIDAZO 2 CARBOXAMIDE; ANTINEOPLASTIC AGENT; IMIDAZOTHIOXANTHONE DERIVATIVE; N [2 (MORPHOLINO)ETHYLO] 11 OXO 11H BENZOTHIOPYRANO[3',2':2,3]PYRIDO[1,2 A]IMIDAZO 2 CARBOXAMIDE; N [3 (DIMETHYLAMINO)PROPYLO] 11 OXO 11H BENZOTHIOPYRANO[3',2':2,3]PYRIDO[1,2 A]IMIDAZO 2 CARBOXAMIDE; THIOXANTHENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER RESISTANCE; CHROMATOPHORE; CLONOGENIC ASSAY; COLON ADENOCARCINOMA; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DRUG DNA INTERACTION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; MOLECULAR MECHANICS; MOLECULAR MODEL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; IMIDAZOLES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, MOLECULAR; NEOPLASMS; OVARIAN NEOPLASMS; XANTHONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 2442606646     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Zee-Cheng RK and Cheng CC: Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino) anthraquinones. J Med Chem 21: 291-294, 1978.
2. Showalter HD, Johnson JL, Werbel LM, Leopold WR, Jackson RC and Elslager EF: 5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation. J Med Chem 27: 253-255, 1984.
3. Leopold WR, Nelson JM, Plowman J and Jackson RC: Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors. Cancer Res 45: 5532-5539, 1985.
4. Archer S, Miller KJ, Rej R, Periana C and Fricker L: Ring-hydroxylated analogues of lucanthone as antitumor agents. J Med Chem 25: 220-227, 1982.
5. Chen Q, Deady LW, Baguley BC and Denny WA: Electron-deficient DNA-intercalating agents as antitumor drugs: aza analogues of the experimental clinical agent N-[2-(dimethylamino) ethyl]acridine-4-carboxamide. J Med Chem 37: 593-597, 1994.
6. Atwell GJ, Rewcastle GW, Baguley BC and Denny WA: Potential antitumor agents. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J Med Chem 30: 664-669, 1987.
7. Antonini I, Polucci P, Kelland LR, Spinelli S, Pescalli N and Martelli S: N4-(omega-Aminoalkyl)-l-[(omega-aminoalkyl) amino]-4-acridinecarboxamides: novel, potent, cytotoxic, and DNA-binding agents. J Med Chem 43: 4801-4805, 2000.
8. Lee HH, Palmer BD, Boyd M, Baguley BC and Denny WA: Potential antitumor agents. Synthesis and antitumor evaluation of dibenzo[1,4]dioxin-1-carboxamides: a new class of weakly binding DNA-intercalating agents. J Med Chem 35: 258-266, 1992.
9. Spicer JA and Denny WA: Synthesis of tetracyclic benzodioxins as potential antitumour agents. Anticancer Drug Des 15: 453-458, 2000.
10. Rewcastle GW, Denny WA and Baguley BC: Potential antitumor agents. Synthesis and antitumor activity of substituted phenazine-1-carboxamides. J Med Chem 30: 843-851, 1987.
11. Gamage SA, Spicer JA, Rewcastle GW, Milton J, Sohal S, Dangerfield W, Mistry P, Vicker N, Charlton PA and Denny WA: Structure-activity relationships for pyrido-, imidazo-, pyrazolo-, pyrazino-, and pyrrolophenazinecarboxamides as topoisomerase-targeted anticancer agents. J Med Chem. 45: 740-743, 2002.
12. Varvaresou A, Tsotinis A, Siatra-Papastaikoudi T, Papadaki-Valiraki A, Thurston DE, Jenkins TC and Kelland LR: Novel imidazothioxanthones: synthesis, DNA binding and cytotoxicity. Bioorg Med Chem Lett 6: 865-870, 1996.
13. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J and Boyd M: Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83: 757-766, 1991.
14. Boyd MR and Paull KD: Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev Res 34: 91-109, 1995.
15. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH and Boyd MR: Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48: 589-601, 1988.
16. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
17. Hamburger AW and Salmon SE: Primary bioassay of human tumor stem cells. Science 197: 461-463, 1977.
18. Berger DP, Henss H, Winterhalter BR and Fiebig HH: The clonogenic assay with human tumor xenografts: evaluation, predictive value and application for drug screening. Ann Oncol 1: 333-341, 1990.
19. Harrap KR, Jones M, Siracky J, Pollard LA and Kelland LR: The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs. Ann Oncol 1: 65-76, 1990.
20. Fichtner I, Naundorf H, Saul GJ, Zschiesche W and Zeisig R: Establishment and characterization of human xenotransplanted breast carcinoma lines: Use for the screening of alkylphosphocholines (APC). Contrib Oncol 51: 129-133, 1996.
21. Double JA and Cifuentes de Castro L: Chemotherapy of transplantable adenocarcinomas of the colon in mice. II. Development and characterization of an ascitic line. Cancer Treat Rep 62: 85-90, 1978.
22. Granovsky AA: www http://classic.chem.msu.su/gran/gamess/index.html
23. Schmidt MW, Baldridge KK, Boatz JA, Elbert ST, Gordon MS, Jensen JJ, Koseki S, Matsunaga N, Nguyen KA, Su S, Windus TL, Dupuis M and Montgomery JA: General atomic and molecular electronic structure system. J Comput Chem 14: 1347-1363, 1993.
24. Scudiero DA, Monks A and Sausville EA: Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen. J Natl Cancer Inst 90: 862, 1998.
25. Pirnia F, Breuleux M, Schneider E, Hochmeister M, Bates SE, Marti A, Hotz MA, Betticher DC and Borner MM: Uncertain identity of doxorubicin-resistant MCF-7 cell lines expressing p53. J Natl Cancer Inst 92: 1535-1536, 2000.